Hong Kong Medical Ad Compliance Checker.

This self-check walks your actual ad copy through the risk areas that most often trip up clinic advertising in Hong Kong, flags the specific phrase (or missing element) that triggered each one, explains which rule it touches, and suggests a compliant rewrite. It's the same discipline our Hong Kong practice team applies when building campaigns for regulated clinic accounts — see the Hong Kong aesthetic clinic marketing and Hong Kong dental clinic marketing pages for the full strategy layer.

What this checker looks for

Nine rule categories, drawn from the sources cited below — each one covers a specific pattern our checker scans your pasted text for:

• Curative/preventive claims for Schedule 1 diseases — Schedule 1 of the Undesirable Medical Advertisements Ordinance prohibits advertisements likely to lead to the use of any medicine, surgical appliance or treatment for treating or preventing a specified list of serious diseases/conditions — including tumours (benign or malignant), sexually transmitted diseases, cardiovascular disease, diabetes, asthma, epilepsy, paralysis, tuberculosis and hepatitis. A narrow exception exists for relief of minor symptoms only (e.g. relieving cold/cough symptoms), never a cure claim. Source↗ (opens in a new tab)
• Sexual function, fertility or gynaecological claims — Schedule 2 of the Undesirable Medical Advertisements Ordinance prohibits advertising for specified purposes including sexual function/fertility enhancement and gynaecological purposes such as menstrual regulation or treatment of amenorrhea. Source↗ (opens in a new tab)
• Cosmetic or corrective surgery advertising — Schedule 2 lists cosmetic or corrective surgery among the prohibited advertising purposes. This is a real risk area for aesthetic-clinic advertising specifically — flagged as a warning rather than an automatic fail because non-surgical aesthetic treatments (injectables, laser, skin treatments) are a different category from surgical procedures, and the exact boundary is a judgement call worth a second look rather than an automatic block. Source
• Testimonials & before/after imagery — Patient testimonials, recommendations, and before/after comparisons implying treatment effect are prohibited in Hong Kong medical advertising — the same restriction pattern applied across Malaysia (KKM), Singapore (MOH/HCSA) and Hong Kong, though each sits under its own distinct ordinance. Source
• Exaggerated or superlative claims — Exaggerated or superlative terms such as "best", "only", "most effective" or "guaranteed success" are prohibited in Hong Kong medical advertising — the rule targets the promotional framing itself, not whether the underlying claim happens to be provable. Source
• Anti-ageing / rejuvenation claims — Claims about restoring youth or reversing ageing sit alongside the same demand-creation/exaggerated-effect concerns the ordinance targets, particularly where paired with a specific medical or cosmetic treatment. Source
• Abortion-related advertising — Any advertisement offering or promoting abortion or miscarriage procedures is absolutely prohibited under Hong Kong's medical advertising rules — no exception applies. Source↗ (opens in a new tab)
• Oral health-supplement claims (Schedule 4) — Since 1 June 2012, Schedule 4 restricts six groups of claims for orally consumed products (health supplements, functional foods, etc.). Prevention/elimination/treatment of breast lumps, regulation of the genitourinary system, and regulation of the endocrine system are not allowed under any circumstances. Regulation of blood sugar/glucose, blood pressure, and blood lipids/cholesterol permit only 4 prescribed claims per category (e.g. the Drug Office's own example: "The product is suitable for people concerned about blood sugar.") — no similar or paraphrased wording is allowed. Products not registered under the Chinese Medicine Ordinance or the Pharmacy and Poisons Ordinance must additionally carry a specified disclaimer alongside any permitted claim. Source↗ (opens in a new tab)
• PDPO — direct-marketing consent (missing opt-out) — Separately from UMAO, the Personal Data (Privacy) Ordinance (PDPO) requires informing a person what personal data will be used for and giving a clear opt-out before it's used for direct marketing. This check only fires once there's substantial pasted text to judge (an empty box isn't "missing an opt-out") — it flags copy that collects data (a form, a booking flow) with no visible consent/opt-out language at all. Source↗ (opens in a new tab)

Methodology — where this checklist comes from

Rules marked "verified" in our sourcing were fetched directly from official Drug Office guideline PDFs (drugoffice.gov.hk), the Privacy Commissioner's own guidance (pcpd.org.hk), or a cross-referenced legal expert guide (cms.law), and read in full — the Schedule 4 orally-consumed-product rule specifically cites the Drug Office's own Annex B Supplementary Guidelines PDF and its official FAQ, both read directly after the primary legislation portal (elegislation.gov.hk) returned only a JavaScript loading shell rather than rendered schedule text.

The Schedule 1/2 disease and purpose lists specifically remain sourced via a Hong Kong clinic-industry compliance summary, because no working primary rendering of those two schedules could be found this session either — logged here rather than silently worked around, the same discipline our Singapore MOH checker already applies when its own primary source is blocked. It is not a substitute for legal advice: treat a “no flags” result as a reasonable first pass, not clearance.

Rules current as of: August 2026

Related free tools